Brain Tumours: Research and Treatment

John McDonnell Excerpts

Thursday 8th May 2025 Commons Chamber

[John McDonnell (Hayes and Harlington) (Ind)]

I pay tribute to my hon. Friend the Member for Mitcham and Morden (Dame Siobhain McDonagh) for the way she has pursued this issue seriously and with such emotion. I knew her sister Margaret. She was a Labour party organiser and I knew her for 45 years. She terrified me, to be honest, over the years, but I always admired her commitment to the Labour party and the wider community. I think Margaret would be proud of her sister for the speech she made today and the work that she has done.

I congratulate the Milan group, a women’s group in my constituency—they call themselves a ladies group. It is a group of Asian ladies who came together when one lost their daughter to a brain tumour. They come together every year, including last weekend, when they raised £2,500 for the Brain Tumour Charity. Each year, they get me to do something. This year, I sang in Punjabi, and they had to lock the doors. The previous year, I danced to bhangra music—I tried to purchase the video off them because it was going viral at one point. That raised a large amount of money and shows the commitment in the wider community, as people become more aware of the situation and of the impact of brain tumours, particularly among children. People realise that something must be done.

I want to make a particular point to reinforce what my hon. Friend the Member for Mitcham and Morden has said. There is a desperate need to look at the mechanisms by which new drugs are brought forward and trialled and people can access those trials. I am a member of the all-party parliamentary group on brain tumours, and we met one family who were desperate to get on to a trial of a particular drug, but the drug was being delayed through the mechanisms we have at the moment. I completely understand the processes we have to go through to ensure that a drug is safe and does not cause harm, but there is frustration at how long that takes and the fact that some people who have no other option are not being allowed to access those trials quickly or effectively enough. On that one occasion, we met the drug company, and as an all-party group, I think we did have a beneficial effect in bringing forward the trials and enabling some of the sufferers to access those trials, which we hope will be successful.

One of the most important points my hon. Friend made is that the system just is not working at the moment. It is producing an element of frustration and a lack of confidence in the NHS, which is disappointing. That is because the treatments are not being brought forward quickly enough, the access to the trials is tortuous to say the least, and there does not seem to be any mechanism by which we are co-ordinating better with the pharmaceutical industry and trying to set priorities for it. My hon. Friend mentioned why the industry concentrates on other cancers—because that is where the big profits are—but there has to be some way in which we can incentivise these companies to focus on this range of conditions.

The problem is that there are so many types of brain tumour, and it is difficult to see a company investing a large amount of money when there might be only a limited impact on a small group of patients. However, that is where Government come in. The resourcing of the experimentation, research and trials is so important, and that falls to the state. My hon. Friend has made the point in previous debates and in meetings of our all-party group that, even where the money is there to enable that to happen, it is not getting out there. We have gone through the different organisational structures to investigate what the issue is. I think it is a lack of leadership, and that needs to come from Government.

One of the suggestions I put to the Minister is that there needs to be a conference—it might be a one-off—where we bring everybody together again. The Government have put forward their proposals in the cancer strategy, and they have looked at the pathways, but a new element of zest is needed. We need to bring the pharmaceutical companies in and have an honest discussion about whether the existing structures are working well enough and whether there needs to be some rationalisation, to ensure that we are more effective and speedy in our actions and to investigate what the pharmaceutical companies need in order for research to be undertaken speedily, more effectively and with greater patient access.

As the hon. Member for Edinburgh West (Christine Jardine) said, there is an issue with the funding of individual drugs. If there is to be a rationing process, it is better to be open and transparent about how rational the implementation is across England, Scotland and Wales. At the moment, there seems to be a bit of a postcode lottery in people’s ability to access these individual drugs, in particular when they are being developed for trial.

We need a fresh initiative. I am sure the Government will commit to doing all they can in the coming period, and I hope that more resources will be applied, but unless we get the structures right, the application of those resources will be as frustrating as it is at the moment. As I think the Minister can understand, there has been an expression of frustration at each of our all-party group’s meetings, because the structures are not implementing what the Government themselves want: the wise investment of resources and a more effective link-up with private sector pharmaceutical companies. We need some form of breakthrough event to enable us to move forward more effectively and more rapidly.

Finally, I pay tribute to the various charities, including the Brain Tumour Charity, that are doing such hard work to raise funds and to give hope and comfort to people as their families go through this appalling experience. I thank them for all the support they have given us in the all-party group.

--- Later in debate ---

[John McDonnell]

I pay tribute to Mr and Mrs Atwal in my constituency, who lost their daughter and have been doing fundraising. One of the most effective things they have been doing is ensuring that at local community events there is a stall that provides information about how to access a diagnosis. That has proved to be incredibly effective, as a range of other professionals have picked up on the information. I pay tribute to Mr and Mrs Atwal for their creativity.

[Shockat Adam]

This is about awareness campaigns. People should be aware that 39%—I think—of children unfortunately diagnosed with a brain tumour experience some kind of sight loss or vision changes, and one in three people diagnosed report a problem with their vision that converts into a brain tumour. An eye test cannot detect all brain tumours, but it is a really valuable tool.

Over 112,000 people have signed a petition demanding that brain tumour research is no longer left behind. These are not just signatures; as we have heard from today’s powerful testimonies, they are families, and they are stories of lives cut short and missed chances. We cannot allow that to continue any longer.